{"title":"程序性细胞死亡蛋白1/程序性死亡配体1在表皮生长因子受体基因罕见突变非小细胞肺癌患者中的表达及临床意义：一项回顾性队列研究","authors":"Yuan Du, Zeliang Zhuang, Lijun Zong, Yongxing Xu","doi":"10.25259/Cytojournal_136_2024","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Lung cancer represents a major global health issue and serves as a leading cause of cancer-related deaths, with non-small cell lung cancer (NSCLC) accounting for a considerable proportion of these cases. This study aimed to investigate the expressions and clinical importance of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) in patients with rare mutations of the epidermal growth factor receptor (<i>EGFR</i>) gene in NSCLC.</p><p><strong>Material and methods: </strong>A retrospective analysis including 121 NSCLC patients with rare EGFR mutations was performed. Immunohistochemistry was conducted to assess PD-L1 expression, and patients were categorized into PD-L1-negative (PLN, <i>n</i> = 95) and PD-L1-positive (PLP, <i>n</i> = 26) groups. PD-1 expression was also evaluated, with patients divided into PD-1-negative (PN, <i>n</i> = 93) and PD-1-positive (PP, <i>n</i> = 25) groups. The associations among PD-L1/PD-1 expression and demographic characteristics, progression-free survival (PFS), overall survival (OS), and a 5-year survival period were analyzed.</p><p><strong>Results: </strong>Significant negative correlations were observed between PD-L1 expression and PFS (r = -0.202, R<sup>2</sup> = 0.041, <i>P</i> = 0.026) and OS (r = -0.204, R<sup>2</sup> = 0.042, <i>P</i> = 0.024). The PLN group exhibited a significantly longer PFS (13.47 ± 3.58 months) than the PLP group (11.67 ± 3.67 months; t = 2.222, <i>P</i> = 0.032) and longer OS (21.39 ± 5.69 months) compared with the PLP group (18.65 ± 4.32 months; t = 2.664, <i>P</i> = 0.010). For PD-1 expression, a negative correlation with PFS was noted (r = -0.325, R<sup>2</sup> = 0.106, <i>P</i> < 0.001). The PN group displayed longer PFS (14.36 ± 3.18 months) and OS (21.71 ± 5.82 months) compared with the PP group (PFS: 11.98 ± 3.72 months, OS: 20.01 ± 5.18 months).</p><p><strong>Conclusion: </strong>This study underscored the importance of PD-1 and PD-L1 expression as prognostic and predictive markers in NSCLC patients with uncommon EGFR mutations. These biomarkers are crucial for achieving informed treatment choices and enhancement of prognostic evaluations in this specific group.</p>","PeriodicalId":49082,"journal":{"name":"Cytojournal","volume":"22 ","pages":"36"},"PeriodicalIF":3.1000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12134896/pdf/","citationCount":"0","resultStr":"{\"title\":\"Expression and clinical significance of programmed cell death protein 1/programmed death-ligand 1 in non-small cell lung cancer patients with rare mutations of epidermal growth factor receptor gene: A retrospective cohort study.\",\"authors\":\"Yuan Du, Zeliang Zhuang, Lijun Zong, Yongxing Xu\",\"doi\":\"10.25259/Cytojournal_136_2024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Lung cancer represents a major global health issue and serves as a leading cause of cancer-related deaths, with non-small cell lung cancer (NSCLC) accounting for a considerable proportion of these cases. This study aimed to investigate the expressions and clinical importance of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) in patients with rare mutations of the epidermal growth factor receptor (<i>EGFR</i>) gene in NSCLC.</p><p><strong>Material and methods: </strong>A retrospective analysis including 121 NSCLC patients with rare EGFR mutations was performed. Immunohistochemistry was conducted to assess PD-L1 expression, and patients were categorized into PD-L1-negative (PLN, <i>n</i> = 95) and PD-L1-positive (PLP, <i>n</i> = 26) groups. PD-1 expression was also evaluated, with patients divided into PD-1-negative (PN, <i>n</i> = 93) and PD-1-positive (PP, <i>n</i> = 25) groups. The associations among PD-L1/PD-1 expression and demographic characteristics, progression-free survival (PFS), overall survival (OS), and a 5-year survival period were analyzed.</p><p><strong>Results: </strong>Significant negative correlations were observed between PD-L1 expression and PFS (r = -0.202, R<sup>2</sup> = 0.041, <i>P</i> = 0.026) and OS (r = -0.204, R<sup>2</sup> = 0.042, <i>P</i> = 0.024). The PLN group exhibited a significantly longer PFS (13.47 ± 3.58 months) than the PLP group (11.67 ± 3.67 months; t = 2.222, <i>P</i> = 0.032) and longer OS (21.39 ± 5.69 months) compared with the PLP group (18.65 ± 4.32 months; t = 2.664, <i>P</i> = 0.010). For PD-1 expression, a negative correlation with PFS was noted (r = -0.325, R<sup>2</sup> = 0.106, <i>P</i> < 0.001). The PN group displayed longer PFS (14.36 ± 3.18 months) and OS (21.71 ± 5.82 months) compared with the PP group (PFS: 11.98 ± 3.72 months, OS: 20.01 ± 5.18 months).</p><p><strong>Conclusion: </strong>This study underscored the importance of PD-1 and PD-L1 expression as prognostic and predictive markers in NSCLC patients with uncommon EGFR mutations. These biomarkers are crucial for achieving informed treatment choices and enhancement of prognostic evaluations in this specific group.</p>\",\"PeriodicalId\":49082,\"journal\":{\"name\":\"Cytojournal\",\"volume\":\"22 \",\"pages\":\"36\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12134896/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cytojournal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.25259/Cytojournal_136_2024\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytojournal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.25259/Cytojournal_136_2024","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
肺癌是一个主要的全球健康问题，是癌症相关死亡的主要原因，非小细胞肺癌（NSCLC）占这些病例的相当大比例。本研究旨在探讨程序性细胞死亡蛋白1 （PD-1）和程序性死亡配体1 （PD-L1）在非小细胞肺癌中表皮生长因子受体（EGFR）基因罕见突变患者中的表达及其临床意义。材料和方法：对121例罕见EGFR突变的非小细胞肺癌患者进行回顾性分析。采用免疫组化方法检测PD-L1表达，将患者分为PD-L1阴性组（PLN, n = 95）和PD-L1阳性组（PLP, n = 26）。将患者分为PD-1阴性组（PN, n = 93）和PD-1阳性组（PP, n = 25），评估PD-1的表达。分析PD-L1/PD-1表达与人口学特征、无进展生存期（PFS）、总生存期（OS）和5年生存期之间的关系。结果：PD-L1表达与PFS （r = -0.202, R2 = 0.041, P = 0.026）、OS （r = -0.204, R2 = 0.042, P = 0.024）呈显著负相关。PLN组PFS（13.47±3.58个月）明显长于PLP组（11.67±3.67个月）；t = 2.222, P = 0.032)， OS（21.39±5.69个月）较PLP组(18.65±4.32个月；t = 2.664, P = 0.010)。PD-1表达与PFS呈负相关（r = -0.325, R2 = 0.106, P < 0.001）。PN组PFS（14.36±3.18个月）和OS（21.71±5.82个月）较PP组（PFS: 11.98±3.72个月，OS: 20.01±5.18个月）更长。结论：本研究强调了PD-1和PD-L1表达作为罕见EGFR突变的非小细胞肺癌患者预后和预测指标的重要性。这些生物标志物对于在这一特定群体中实现明智的治疗选择和加强预后评估至关重要。
Expression and clinical significance of programmed cell death protein 1/programmed death-ligand 1 in non-small cell lung cancer patients with rare mutations of epidermal growth factor receptor gene: A retrospective cohort study.
Objective: Lung cancer represents a major global health issue and serves as a leading cause of cancer-related deaths, with non-small cell lung cancer (NSCLC) accounting for a considerable proportion of these cases. This study aimed to investigate the expressions and clinical importance of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) in patients with rare mutations of the epidermal growth factor receptor (EGFR) gene in NSCLC.
Material and methods: A retrospective analysis including 121 NSCLC patients with rare EGFR mutations was performed. Immunohistochemistry was conducted to assess PD-L1 expression, and patients were categorized into PD-L1-negative (PLN, n = 95) and PD-L1-positive (PLP, n = 26) groups. PD-1 expression was also evaluated, with patients divided into PD-1-negative (PN, n = 93) and PD-1-positive (PP, n = 25) groups. The associations among PD-L1/PD-1 expression and demographic characteristics, progression-free survival (PFS), overall survival (OS), and a 5-year survival period were analyzed.
Results: Significant negative correlations were observed between PD-L1 expression and PFS (r = -0.202, R2 = 0.041, P = 0.026) and OS (r = -0.204, R2 = 0.042, P = 0.024). The PLN group exhibited a significantly longer PFS (13.47 ± 3.58 months) than the PLP group (11.67 ± 3.67 months; t = 2.222, P = 0.032) and longer OS (21.39 ± 5.69 months) compared with the PLP group (18.65 ± 4.32 months; t = 2.664, P = 0.010). For PD-1 expression, a negative correlation with PFS was noted (r = -0.325, R2 = 0.106, P < 0.001). The PN group displayed longer PFS (14.36 ± 3.18 months) and OS (21.71 ± 5.82 months) compared with the PP group (PFS: 11.98 ± 3.72 months, OS: 20.01 ± 5.18 months).
Conclusion: This study underscored the importance of PD-1 and PD-L1 expression as prognostic and predictive markers in NSCLC patients with uncommon EGFR mutations. These biomarkers are crucial for achieving informed treatment choices and enhancement of prognostic evaluations in this specific group.
期刊介绍：
The CytoJournal is an open-access peer-reviewed journal committed to publishing high-quality articles in the field of Diagnostic Cytopathology including Molecular aspects. The journal is owned by the Cytopathology Foundation and published by the Scientific Scholar.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
